Clinical Trial Update: Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency [Phase 2]

View source ↗

Summary

An ongoing Phase 2 clinical trial is testing induction therapy with bortezomib, isatuximab, cyclophosphamide, and dexamethasone in transplant-eligible multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Decadron (Dexamethasone)
• SARCLISA (isatuximab)
• Velcade (bortezomib)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING